On Jun. 2, 2014, Omeros received U.S. Food and Drug Administration (FDA) approval of Omidria for use in cataract and other intraocular lens replacement procedures. Omeros was founded in Seattle in In 1994 as a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.

The company launched its Initial Public Offering in 2009 at $10.00 per share and raised $62.1 million in net proceeds.